- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials -
- Eleven poster presentations highlighting plazomicin’s activity against MDR Enterobacteriaceae, including
carbapenem-resistant Enterobacteriaceae (CRE) -
SOUTH SAN FRANCISCO, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical
company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced 13
upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting. The Company and
its collaborators will deliver two oral presentations and 11 poster presentations at the event, which will be held in New Orleans,
LA from June 1 to 5, 2017. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due
to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Oral Presentations
| Title: |
|
Evaluating Once-Daily Plazomicin versus Meropenem for the Treatment
of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Results from a Phase 3 Study (EPIC) |
| Authors: |
|
D.Cloutier (presenter), L.Miller, A.Komirenko, D.Cebrik, T.Keepers,
K.Krause, L.Connolly, F.Wagenlehner |
| Session: |
|
Urinary Tract Infections: New Concepts |
| |
|
Sunday, June 4, 2017, 4:45 - 5:00pm ET |
| |
|
|
| Title: |
|
Plazomicin (PLZ) Associated with Improved Survival and Safety
Compared to Colistin (CST) in Serious Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Results of
the CARE Study |
Authors:
|
|
G.Daikos, L.Connolly (presenter), A.Jubb, B.O'Keeffe, A.Serio,
A.Smith, J.Gall, K.Krause, J.McKinnell, E.Zakynthinos, V.Riddle
|
| Session: |
|
Development of New Drugs and Strategies for Hospital-acquired
Pneumonia Caused by MDR Pathogens |
| |
|
Saturday, June 3, 2017, 4:45 - 5:00pm ET |
Key Poster Presentations
| Title: |
|
In Vitro Activity of Plazomicin and Comparator Agents
against Urinary Tract Infection Isolates from the United States and Europe |
| Authors: |
|
M. Castanheira, T.Doyle, A.Serio, K.Krause, J.Streit, R.Flamm |
| Session: |
|
335 - AAID - Design, Evaluation, Combination and Antibacterial
Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET |
| |
|
|
| Title: |
|
Aminoglycoside-Resistant Genes among 2014-2015 US
Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized
Isolates |
| Authors: |
|
M. Castanheira, L.Woosley, T.Doyle, A.Serio, K.Krause, R.Flamm |
| Session: |
|
335 - AAID - Design, Evaluation, Combination and Antibacterial
Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET |
Additional Poster Presentations
| Title: |
Impact of Changes in Growth Medium, Inoculum Density and Incubation
Conditions on the In Vitro Antimicrobial Activity of Plazomicin (Poster #410) |
| Authors: |
L.Duncan, P.Rhomberg, B.Schaefer, R.Flamm, A.Serio, K.Krause,
M.Castanheira |
| Session: |
Session 057 - CPHM02 - Antimicrobial Susceptibility Testing I
|
| |
Friday, June 2, 2017, 12:45 - 2:45pm ET |
| |
|
| Title: |
Comparison of Agar Dilution and Broth Microdilution Plazomicin MICs
(Poster #416) |
| Authors: |
M. Hackel, A.Serio, K.Krause, D. Sahm |
| Session: |
Session 205 - CPHM02 - Antimicrobial Susceptibility Testing II
|
| |
Saturday June 3, 2017, 12:15 - 2:15pm ET |
| |
|
| Title: |
Antimicrobial Activity of Plazomicin
against Enterobacteriaceae Producing Carbapenemases from 50 Brazilian Medical Centers (Poster #2) |
| Authors: |
A.Martins, F.Tuon, L.Bail, C.Ito, J.Rocha, A.Serio,
T.Dalmolin |
| Session: |
335 - AAID - Design, Evaluation, Combination and Antibacterial
Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET
|
| |
|
| Title: |
In Vitro Activity of Plazomicin against Gram-Negative and
Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011-2015: CANWARD Surveillance Study (Poster #3) |
| Authors: |
G.Zhanel, H.Adam, M.Baxter, A.Denisuik, A.Walkty, P.Lagace-Wiens,
F.Schweizer, D.Hoban, J.Karlowsky |
| Session: |
335 - AAID - Design, Evaluation, Combination and Antibacterial
Activity of New Drugs, Sunday, June 4, 2017, 12:15 - 2:15pm ET |
| Title: |
In Vitro Activity of Plazomicin (PLZ) and Comparators against
Facultative Anaerobes Incubated Aerobically and Anaerobically and Obligate Anaerobes (Poster #333) |
| Authors: |
D.Citron, K.Tyrrell, E.Leoncio, A.Serio, K.Krause, E.Goldstein |
| Session: |
351 - AAID11 - New Antimicrobial Agents: New Antibacterial Agents II
|
| |
Sunday, June 4, 2017, 12:15 - 2:15pm ET |
| |
|
| Title: |
Investigating the Post-Antibiotic Effect of Plazomicin against
Multidrug Resistant Enterobacteriaceae (Poster #205) |
| Authors: |
D.Hall, M.Thwaites, D.Shinabarger, A.Serio,
K.Krause, C.Pillar |
| Session: |
341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET
|
| |
|
| Title: |
Pharmacokinetics (PK) of Plazomicin in Healthy Adults (Poster
#206) |
| Authors: |
J.Seroogy, T.Choi, J.Gall, S.Van Wart, S.Dhuria |
| Session: |
341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET
|
| |
|
| Title: |
The Pharmacodynamics (PD) of Plazomicin (PLZ) and Amikacin (AMK)
against Enterobacteriaceae Studied in an In VitroPharmacokinetic (PK) Model of Infection
(Poster #203) |
| Authors: |
K.Bowker, A.Noel, M.Attwood, S.Tomaselli, A.MacGowan, A.Kim,
K.Krause |
| Session: |
341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET
|
| |
|
| Title: |
Tissue Distribution of [14C]-Plazomicin in Rats (Poster
#204) |
| Authors: |
T.Choi, J.Seroogy, H.Patel |
| Session: |
341 - AAID03 - Antimicrobial Pharmacokinetics: PK/PD of New
Antimicrobial Agents, Sunday, June 4, 2017, 12:15 - 2:15pm ET
|
The abstracts can be accessed through the ASM Microbe website. Following the meeting, the presentation slides and posters will be
available on the Achaogen website.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of
innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product
candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant
Enterobacteriaceae. The U.S. Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment
of bloodstream infections (BSI) caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment
options. Achaogen’s plazomicin program is funded in part with Federal funds from the Biomedical Advanced Research and Development
Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health
and Human Services, under Contract No. HHSO100201000046C. Plazomicin is the first clinical candidate from Achaogen’s gram-negative
antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR
gram-negative infections. All product candidates are investigational only and have not been approved for
commercialization. For more information, please visit www.achaogen.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein
are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s expectations
regarding potential regulatory approval of plazomicin, Achaogen’s commercial objectives and Achaogen’s pipeline of product
candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may
cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the
uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval
process; the risks and uncertainties of commercialization and gaining market acceptance; the risk when bacteria will evolve
resistance to plazomicin; Achaogen's reliance on third-party contract manufacturing organizations to manufacture and supply its
product candidates and certain raw materials used in the production thereof; risk of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's
proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks
and uncertainties that could cause actual results to differ from those expressed in these forward- looking statements, as well as
risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 14, 2017. Achaogen
does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of
any new information, future events, changed circumstances or otherwise.
Source: Achaogen, Inc.
AKAO-G
Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com
